January 16, 2020 With so few current treatment options for lupus and lupus nephritis, patients may benefit from joining a clinical study. Right now, five national trials are testing interventions for lupus nephritis that you may be able to join. To learn more about these and over 150 other trials for lupus and its many […] READ MORE
January 16, 2020 Up to half of people with lupus will have lupus nephritis – damage to the kidneys that affects the ability to clear the body of wastes and toxins. In 2020, we expect to see significant progress in new drug development for lupus and lupus nephritis in particular with submissions for FDA approval in […] READ MORE
January 16, 2020 The Lupus Research Alliance has invested millions in research to get us to the point we’re at with potential new treatments for LN. We are proud to share what just ten of our funded scientists are doing right now to discover what causes lupus nephritis and how it can be better diagnosed, […] READ MORE
January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […] READ MORE
January 6, 2020 New research published in Arthritis and Rheumatology shows that peripheral nervous system (PNS) disease is an important part of neuropsychiatric lupus with significant effects on quality of life. The peripheral nervous system is the network that sends signals between the brain and spinal cord (the central nervous system) with all the other […] READ MORE
Throughout its history, the LRA has played a pivotal role in bringing together the key players in the fight against lupus and 2019 is no exception. More than 100 of the world’s top scientists in lupus research and treatment gathered on October 20-22 for the LRA’s 2019 annual three-day Forum for Discovery scientific conference. Researchers […] READ MORE
December 18, 2019 The Lupus Research Alliance (LRA) welcomes additional positive results published today in the New England Journal of Medicine online edition from AstraZeneca’s Phase 3 TULIP-2 trial studying the investigational biologic anifrolumab as a treatment for systemic lupus erythematosus (SLE or lupus). The new study provides further details showing that anifrolumab, which targets […] READ MORE
December 17, 2019 The Lupus Research Alliance is thrilled to share exciting news from GSK that Benlysta (belimumab) demonstrated positive clinical trial results in treating lupus nephritis (LN), a common complication of lupus causing inflammation of the kidneys that can result in end-stage kidney disease. Called BLISS-LN, this Phase 3 trial is the largest one […] READ MORE
December 16, 2019 Lupus Research Alliance advocates have good reason to pat themselves on the back today! The 2020 Defense Appropriations Act, on which Congress will vote in the coming days, would provide exactly what in-person and virtual advocates requested during “The Lupus Research Alliance 15th Annual Advocate for Lupus Research Hill Day” in March. […] READ MORE
Thinking outside the box” is jargon that often rings hollow—but not so when it’s used to describe the ideas generated by Ignacio Sanz, MD, world-renowned expert on autoimmunity. Dr. Sanz recently discovered that certain little-understood immune system cells are a major source of the harmful proteins that promote lupus symptoms. This breakthrough has the potential […] READ MORE
Leading with Extraordinary Clarity and Grace The LRA is enormously grateful to Mary K. (Peggy) Crow, MD for her more than 10 years of devoted service and leadership as the organization’s Co-Chair of our Scientific Advisory Board. Dr. Crow’s tenure concludes on December 31st. “It’s well known that Dr. Crow has brought vision … leadership […] READ MORE
BIG … BOLD … IDEAS ARE TRANSFORMING LUPUS RESEARCH—thanks to people like you! Thanks to our remarkable supporters, the Lupus Research Alliance awarded nearly $7.5 million through the following grant mechanisms in 2019: 2019 Novel Research Grants ($1,798,602) Carla Cuda, PhD The Role of Microglial Subsets in Driving Neuropsychiatric Symptoms of SLE Northwestern University – Chicago […] READ MORE
